Retrospective review of efficacy and safety of 0.05% and 0.01 % atropine eyedrop using for suppressing myopia progression in school-age children treated at Siriraj hospital

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

TCTR

Registry ID

TCTR20220930002

Enrollment

244

Registered

2022-09-30

Start date

2022-09-06

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retrospective review of efficacy and safety of 0.05% and 0.01 % atropine eyedrop using for suppressing myopia progression in school-age children treated at Siriraj hospital Atropine eyedrop, suppressing myopia progression, school-age children

Interventions

treat with 0.05%atropine eye drops at 1 year,treat with 0.01%atropine eye drops at 1 year

Treatment,Treatment

0.05% atropine,0.01% atropine

Eligibility

Sex/Gender

All

Age

5 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1) Aged 5-18 years 2) Spherical equivalent (SE) more than -1.00 D 3) myopia change more than 0.5 D in 1 year before drug starting 4) Treat myopia with eyeglasses only 5) Not treat with atropine eye drops before

Exclusion criteria

Exclusion criteria: 1) other eye diseases such as lazy eye, corneal lesions, cataracts, glaucoma, pterygium and eye cancer 2) Myopia after surgery 3) Not able to complete information in the period of study

Design outcomes

Primary

Measure	Time frame
compare spherical equivalent between groups first visit and 1 year later Mann-Whitney U test	—

Secondary

Measure	Time frame
compare spherical equivalent in group first visit and 1 year later Wilcoxon sign rank test	—

Countries

Thailand

Contacts

Public ContactAssoc.Prof.Thammanoon Surachatkumtonekul

Faculty of Medicine Siriraj Hospital, Mahidol University

si95thim@gmail.com024198037

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026